Keros Therapeutics, Inc. (KROS) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 9 recommend buying, 7 recommend holding, and 0 recommend selling.
The analyst consensus price target for KROS is $102.60, representing a +788.3% upside from the current price of $11.55. Price targets range from a low of $96.00 to a high of $107.00.
